Evaluating nanoparticle localisation in glioblastoma multicellular tumour spheroids by surface enhanced Raman scattering.
Journal
The Analyst
ISSN: 1364-5528
Titre abrégé: Analyst
Pays: England
ID NLM: 0372652
Informations de publication
Date de publication:
10 Jul 2023
10 Jul 2023
Historique:
medline:
12
7
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is a particularly aggressive and high-grade brain cancer, with poor prognosis and life expectancy, in urgent need of novel therapies. These severe outcomes are compounded by the difficulty in distinguishing between cancerous and non-cancerous tissues using conventional imaging techniques. Metallic nanoparticles (NPs) are advantageous due to their diverse optical and physical properties, such as their targeting and imaging potential. In this work, the uptake, distribution, and location of silica coated gold nanoparticles (AuNP-SHINs) within multicellular tumour spheroids (MTS) derived from U87-MG glioblastoma cells was investigated by surface enhanced Raman scattering (SERS) optical mapping. MTS are three-dimensional
Identifiants
pubmed: 37366648
doi: 10.1039/d3an00751k
pmc: PMC10332387
doi:
Substances chimiques
Tenascin
0
Gold
7440-57-5
Silicon Dioxide
7631-86-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3247-3256Subventions
Organisme : Medical Research Council
ID : MR/V038303/1
Pays : United Kingdom
Références
Analyst. 2018 Dec 3;143(24):5965-5973
pubmed: 30225477
Front Med Technol. 2022 Jun 15;4:909943
pubmed: 35782575
Radiother Oncol. 2014 Feb;110(2):342-7
pubmed: 24444528
Chem Sci. 2020 May 27;11(22):5819-5829
pubmed: 34094083
PLoS One. 2016 Dec 9;11(12):e0167548
pubmed: 27936027
Nanomedicine (Lond). 2016 Mar;11(6):673-92
pubmed: 27003448
Cancers (Basel). 2021 Mar 23;13(6):
pubmed: 33806801
Talanta. 2019 Jan 1;191:390-399
pubmed: 30262075
Analyst. 2016 Jan 7;141(1):100-10
pubmed: 26456100
Chem Sci. 2022 Feb 25;13(12):3468-3476
pubmed: 35432863
Int J Nanomedicine. 2019 Aug 28;14:6957-6970
pubmed: 32021157
Front Chem. 2019 Jun 04;7:410
pubmed: 31214580
Cancer Res. 2013 Jan 1;73(1):319-30
pubmed: 23074284
Int J Exp Pathol. 1998 Feb;79(1):1-23
pubmed: 9614346
Nat Protoc. 2013 Jan;8(1):52-65
pubmed: 23237829
Anal Chem. 2017 Dec 5;89(23):12666-12673
pubmed: 28985467
Anal Chem. 2021 Apr 13;93(14):5862-5871
pubmed: 33797884
Sci Rep. 2020 Apr 2;10(1):5809
pubmed: 32242067
J Histochem Cytochem. 2018 Apr;66(4):289-304
pubmed: 29385356
Front Cell Dev Biol. 2021 Apr 29;9:674199
pubmed: 33996833
Front Oncol. 2022 Aug 12;12:971462
pubmed: 36033448
J Mol Neurosci. 2021 Aug;71(8):1636-1647
pubmed: 33876384
J Cell Sci. 2016 Dec 1;129(23):4321-4327
pubmed: 27875272
Neuro Oncol. 2016 Apr;18(4):507-17
pubmed: 26320116
Sci Rep. 2020 Jul 14;10(1):11583
pubmed: 32665565
Front Mol Biosci. 2021 Jul 01;8:683519
pubmed: 34277702
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
J Cell Commun Signal. 2009 Dec;3(3-4):287-310
pubmed: 19838819
Analyst. 2015 Jun 21;140(12):3910-20
pubmed: 25923379
Oncotarget. 2017 Jan 3;8(1):1725-1736
pubmed: 27965457
J Control Release. 2022 Jan;341:661-675
pubmed: 34915071
Chem Soc Rev. 2016 Apr 7;45(7):1901-1918
pubmed: 26691004
Small. 2014 Oct 15;10(19):3954-61
pubmed: 24990320
Nano Lett. 2006 Apr;6(4):662-8
pubmed: 16608261
Cancer Lett. 2006 Dec 8;244(2):143-63
pubmed: 16632194